

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(use as many sheets as necessary)

Sheet 2 of 5

Application Number	10/018,273
Filing Date	08-07-2002
First Named Inventor	PERRICAUDET
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	ST99019 - US - PCT

RECEIVED
JUN 02 2003
H CENTER
CENTER
1600/2900



[illegible][illegible]

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	10/018,273
Filing Date	08-07-2002
First Named Inventor	PERRICAUDET
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	ST99019 - US - PCT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
hsp		Agnes Paire et al., Characterization of the Rat Thyroid Iodide Transporter Using Anti-Peptide Antibodies, Journ. of Bio. Chem., Vol. 272, No. 29, July 18, 1997, pp. 18425-18249	
		Andre Lieber et al., Recombinant Adenoviruses with Large Deletions Generated by Cre-Mediated Excision Exhibit Different Biological Properties Compared with First-Generation Vectors In Vitro and In Vivo, Journ. of Virology, Vol. 70, No. 12, Dec. 1996, pp. 8944-8960	
		Valerie Kroughliak et al., Development of Cell Lines Capable of Complementing E1, E4, and Protein IX Defective Adenovirus Type 5 Mutants, Human Gene Therapy, Vol. 6, Dec. 1995, pages 1575-1586	
		Douglas Hanahan, Heritable Formation Of Pancreatic Beta-cell Tumours in Transgenic Mice Expressing Recombinant Insulin/Simian Virus 40 Oncogenes, Nature, Vol. 315, May 9, 1985, pp. 115-122	
		Ge Dai et al., Cloning And Characterization of the Thyroid Iodide Transporter, Nature, Vol. 379, Feb. 1996, pp. 458-460	
		Goutam Ghosh-Choudhury et al., Human Adenovirus Cloning Vectors Based on Infectious Bacterial Plasmids, Gene, Vol. 50, 1986, pages 161-171	
		Harry R. Maxon et al., Relation Between Effective Radiation Dose and Outcome of Radioiodine Therapy For Thyroid Cancer, NEJM, Vol. 309, No. 16, Oct. 20, 1983	
		J-Y Cho et al., Expression And Activity Of Human Na ⁺ /I ⁻ Symporter In Human Glioma Cells By Adenovirus-mediated Gene Delivery (Abstract XP2155151), Gene Therapy, Vol. 7, May, 2000, pages 740-749	
		J. Chroboczek et al., The Sequence Of The Genome of Adenovirus Type 5 and Its Comparison With the Genome of Adenovirus Type 2, Virology, Volume 186, 1992, pages 1-13	
		Joel Crouzet et al., Recombinational Construction in Escherichia Coli of Infectious Adenoviral Genomes, Proc. Natl. Acad. Sci, USA, Vol 94, Feb. 1997, pages 1414-1419	
		John Nemunaitis et al., Phase I Trial of Interferon-γ (IFN-γ) Retroviral Vector Administered Intratumorally To Patients With Metastatic Melanoma, Cancer Gene Therapy, Vol. 6, No. 4, 1999, pages 322-330	

Examiner
Signature

Date
Considered

12/13/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 5

Complete if Known

Application Number 10/018,273
Filing Date 08-07-2002
First Named Inventor PERRICAUDET
Group Art Unit 1614
Examiner Name Unknown
Attorney Docket Number ST99019 - US - PCT

RECEIVED
JUL 02 2003
TECH CENTER 1600/2900

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
h		MANDELL R, Gene Therapy of Cancer by Retroviral Transfer and Expression of the Rate Sodium/Iodide Symporter (NIS), 88th Annual Meeting of the American Association for Cancer Research, San Diego, CA, USA; April 12-16, 1997, Vol. 38, 1997, page 381	
		MANDELL Robert B, Radiosotope Concentrator Gene Therapy Using the Sodium/Iodine Symporter Gene, Cancer Research, Feb. 1, 1999, Vol. 59, No. 3 pages 661-668	
		Massimo Levero et al., Defective And Nondefective Adenovirus Vectors For Expressing Foreign Genes In Vitro and In Vivo, Gene, Vol. 101, 1991, pp. 195-202	
		Michael Boshart et al., A Very Strong Enhancer Is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus, Cell, Vol. 41, June 1985, pages 521-530	
		Orlie Levy et al., N-linked Glycosylation of the Thyroid Na ⁺ /I ⁻ Symporter (NIS), Journ. of Bio. Chem, Vol. 273, August 28, 1998, pp. 22657-22663	
		P.A. Smanik et al., Cloning of the Human Sodium Iodide Symporter, Biochemical and Biophysical Research Communications, 1996, pages 339-345	
		Patrice Yeh et al., Efficient Dual Transcomplementation of Adenovirus E1 and E4 Regions From a 293-Derived Cell Line Expressing a Minimal E4 Functional Unit, Journ. of Virology, Vol. 70, No. 1, Jan. 1996, pp. 559-565	
		Peter C. Van Der Vliet et al., Thermolabile DNA Binding Proteins from Cells Infected With a Temperature-Sensitive Mutant of Adenovirus Defective In Viral DNA Synthesis, Journ. of Virology, Vol. 15, No. 2, Feb. 1975, pages 348-354	
		R. M. Myers, Human STSs, Unpublished, 1997, pages 1-2	
		Toyoshi Endo et al., Thyroid Transcription Factor-1 Activates the Promoter Activity of Rat Thyroid Na ⁺ /I ⁻ Symporter Gene, Molecular Endocrinology Vol. 11, 1997, pages 1747-1755	
		Robin J. Parks et al., A Helper-Dependent Adenovirus Vector System: Removal of Helper Virus by Cre-mediated Excision of the Viral Packaging Signal, Proc. Natl. Acad. Sci., USA, Vol. 93, Nov. 1996, pages 13565-13570	

Examiner
Signature

Date

Considered

12/13/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

☒

+

RECEIVED
JUL 02 2003
INTER 1600/2900


Complete if Known

Application Number	10/018,273
Filing Date	08-07-2002
First Named Inventor	PERRICAUDET
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	ST99019 - US - PCT

(use as many sheets as necessary)

Sheet 5 of 5

Attorney Docket Number	ST99019 - US - PCT
------------------------	--------------------



[illegible]

Examiner
Signature

Date
Considered

12/13/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+